Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Belgian-Dutch drug discovery company Galapagos has seen its stock rise after agreeing to supply Swiss pharmaceuticals giant Roche with its exclusive chemical compound libraries. Galapagos will supply the libraries through its BioFocus unit.
Subscribe to our email newsletter
Although financial details of the agreement were not disclosed, the deal builds on the existing relationship between Roche and BioFocus. Under the terms of the agreement, BioFocus will supply Roche with exclusive chemical compound libraries for a term of three years. Financial terms were not disclosed.
BioFocus will synthesize novel chemical compound libraries based on Roche’s framework structures and provide these collections on an exclusive basis to Roche. These libraries will be generated using a combination of BioFocus’ molecular informatics tools and a wide range of synthetic chemistry capabilities.
The Galapagos subsidiary designs and synthesizes both exclusive as well as non-exclusive (SoftFocus) chemical compound libraries that can be used in drug discovery programs, including hit finding, lead optimization and patent exemplification.
“With a strong set of design tools and world-class synthetic chemistry capabilities, BioFocus continues to secure new business by providing high-quality libraries to the pharmaceutical and biotech industries,” said Onno van de Stolpe, CEO of Galapagos.